Merus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.

About MRUS

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. 

CEO
Jan G. J. van de Winkel
CEOJan G. J. van de Winkel
Employees
260
Employees260
Headquarters
Utrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded
2003
Founded2003
Employees
260
Employees260

MRUS Key Statistics

Market cap
7.35B
Market cap7.35B
Price-Earnings ratio
-18.18
Price-Earnings ratio-18.18
Dividend yield
Dividend yield
Average volume
1.24M
Average volume1.24M
High today
$97.02
High today$97.02
Low today
$96.86
Low today$96.86
Open price
$96.90
Open price$96.90
Volume
501.13K
Volume501.13K
52 Week high
$97.14
52 Week high$97.14
52 Week low
$33.19
52 Week low$33.19

Stock Snapshot

Merus(MRUS) stock is priced at $96.99, giving the company a market capitalization of 7.35B. It carries a P/E multiple of -18.18.

As of 2025-12-22, Merus(MRUS) stock has fluctuated between $96.86 and $97.02. The current price stands at $96.99, placing the stock +0.1% above today's low and -0.0% off the high.

Merus(MRUS) shares are trading with a volume of 501.13K, against a daily average of 1.24M.

During the past year, Merus(MRUS) stock moved between $33.19 at its lowest and $97.14 at its peak.

During the past year, Merus(MRUS) stock moved between $33.19 at its lowest and $97.14 at its peak.

MRUS News

Nasdaq 10h
First Week of MRUS February 2026 Options Trading

Investors in Merus NV (Symbol: MRUS) saw new options begin trading this week, for the February 2026 expiration. At Stock Options Channel , our YieldBoost formul...

First Week of MRUS February 2026 Options Trading
Simply Wall St 6d
Merus: Reassessing Valuation After a 120% Year-to-Date Rally and Strong Multi-Year Returns

Merus (MRUS) has quietly turned into one of the stronger biotech performers this year, with the stock up more than 120% year to date as investors reprice its an...

Merus: Reassessing Valuation After a 120% Year-to-Date Rally and Strong Multi-Year Returns

Analyst ratings

88%

of 16 ratings
Buy
12.5%
Hold
87.5%
Sell
0%

People also own

Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.